Subconjunctival injections of triamcinolone acetonide to treat uveitic macular edema

Qu, Yi; Liu, Xin-Shu; Liang, Anyi; Xiao, Jing; Zhao, Chan; Gao, Fengmei; Zhang, Meifen

doi:10.18240/ijo.2020.07.11

Cited by 2 publications

(2 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Subconjunctival administration involves the injection of therapies into the space between the sclera and the conjunctiva, and are often used for administering drugs for treating posterior segment eye diseases such as uveitis [ 37 ]. However, subconjunctival injections are difficult to administer and not without their risks, where injections of steroids placed over a diseased cornea or sclera can cause thinning, temporary pain, and possibly a rupture at the site of the injection [ 38 ].…”

Section: Current Principal Administration Routes For Ocular Therapiesmentioning

confidence: 99%

Delivery Systems in Ocular Retinopathies: The Promising Future of Intravitreal Hydrogels as Sustained-Release Scaffolds

et al. 2023

View full text Add to dashboard Cite

Slow-release delivery systems are needed to ensure long-term sustained treatments for retinal diseases such as age-related macular degeneration and diabetic retinopathy, which are currently treated with anti-angiogenic agents that require frequent intraocular injections. These can cause serious co-morbidities for the patients and are far from providing the adequate drug/protein release rates and required pharmacokinetics to sustain prolonged efficacy. This review focuses on the use of hydrogels, particularly on temperature-responsive hydrogels as delivery vehicles for the intravitreal injection of retinal therapies, their advantages and disadvantages for intraocular administration, and the current advances in their use to treat retinal diseases.

show abstract

Section: Current Principal Administration Routes For Ocular Therapiesmentioning

confidence: 99%

Delivery Systems in Ocular Retinopathies: The Promising Future of Intravitreal Hydrogels as Sustained-Release Scaffolds

et al. 2023

View full text Add to dashboard Cite

show abstract

“…So far, the published results for such treatment are promising—CST reduction occurs in most patients, with accompanying improvement in visual acuity and relapses in only about a quarter of patients six months after an injection [ 19 ]. Unfortunately, this route of administration can have side effects, especially in the form of an increase in IOP (25% of participants), with some patients requiring surgical rinsing out of triamcinolone.…”

Section: Non-infectious Uveitismentioning

confidence: 99%

Update on the Management of Uveitic Macular Edema

Teper

2021

JCM

View full text Add to dashboard Cite

Uveitic macular edema (ME) is a frequent complication in 8.3% of uveitis patients and is a leading cause of serious visual impairment in about 40% of cases. Despite the numerous available drugs for its treatment, at least a third of patients fail to achieve satisfactory improvement in visual acuity. First-line drugs are steroids administered by various routes, but drug intolerance or ineffectiveness occur frequently, requiring the addition of other groups of therapeutic drugs. Immunomodulatory and biological drugs can have positive effects on inflammation and often on the accompanying ME, but most uveitic randomized clinical trials to date have not aimed to reduce ME; hence, there is no clear scientific evidence of their effectiveness in this regard. Before starting therapy to reduce general or local immunity, infectious causes of inflammation should be ruled out. This paper discusses local and systemic drugs, including steroids, biological drugs, immunomodulators, VEGF inhibitors, and anti-infection medication.

show abstract

Subconjunctival injections of triamcinolone acetonide to treat uveitic macular edema

Cited by 2 publications

References 26 publications

Delivery Systems in Ocular Retinopathies: The Promising Future of Intravitreal Hydrogels as Sustained-Release Scaffolds

Delivery Systems in Ocular Retinopathies: The Promising Future of Intravitreal Hydrogels as Sustained-Release Scaffolds

Update on the Management of Uveitic Macular Edema

Contact Info

Product

Resources

About